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A B S T R A C T
Prostate cancer is a disease of elderly men, hthe incidence of whic increases in an age dependent manner. This study
presents the correlation of clinical and morphological parameters in locally confined (pT2) and locally advanced (pT3)
prostate cancer. We analyzed a group of elderly men treated with radical prostatectomy in the period 1999–2008 in the
University Hospital Rijeka. We found no statistical association between pT stage and age categories, preoperative pros-
tate-specific antigen, digitorectal examination and biopsy Gleason score. There was a significant correlation of higher
Gleason score in prostate specimens after radical prostatectomy and a higher frequency of a positive surgical margin in
tumors with pT3 than in pT2 stage (p=0.003; p=0.011 respectively). Recurrence-free survival was shorter in patients
with tumors with positive surgical margins as well as in patients with pT3 stage (p=0.030; p=0.001 respectively). We
conclude that higher tumor grade and positive surgical margins are indicators of a worse prognosis in our patients.
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Introduction
Prostatic carcinoma is known to be primarily a dis-
ease of elderly men, the incidence of which increases in
an age dependent manner. The incidence of prostate can-
cer varies throughout the world but it is generally higher
in developed western countries with trend of 900,000
newly diagnosed cases per year till 20101–3. The incidence
has been increasing due to a multitude of factors such as
a wide use of serum prostate-specific antigen (PSA) as-
say, the introduction of systematic 12-cylinder ultra-
sound-guided prostate biopsy, an ageing population with
longer life expectancy and a general increase in aware-
ness among doctors. As a result of widespread testing of
patients for PSA most patients present with clinically lo-
calized tumors and low Gleason scores (<6)4,5. The natu-
ral course of this disease is long and extremely variable
with the potential for progression, often during more
than 10 years4,6. Many clinicians have long believed that
prostatic carcinoma takes a less aggressive course in
older patients and suggest that no active therapy is nec-
essary for patients with tumors confined to the organ5,7.
However, in discussing treatment options, watchful wait-
ing is rarely chosen by patients because of fear of future
consequences8. Recent studies favours early, agressive
treatment which provides not only a chance to eradicate
prostate cancer, but offers to otherwise healthy older
men with reasonable life expectancy, prevention of me-
tastasis and recurrence of the cancer. Potentially cura-
tive therapy results in significantly improved life expec-
tancy and quality of life for older men with few co-
morbidities and moderately or even poorly differentiated
localized prostate cancer. Therefore, elderly should not
be denied this way of treatment on the grounds of age
alone6,8–10.
The aim of the present study was to establish the dif-
ferences and associations of clinical and morphological
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parameters with locally confined (pT2) and locally ad-
vanced (pT3) prostate cancer in a group of elderly men
treated with radical prostatectomy.
Patients and Methods
The study included medical records of patents from
the Department of Urology and Department of Oncology
and Radiotherapy Rijeka University Hospital Center in
Rijeka and files kept at the Department of Pathology,
Rijeka University School of Medicine, Rijeka, Croatia.
In the period from 1999 to 2008, 1758 patients were
submitted to ultrasound guided needle biopsy and got di-
agnosis of prostatic adenocarcinoma. Candidates for rad-
ical prostatectomy according to the European Associa-
tion of Urologya criteria had Gleason score 7 or less, PSA
less than 10 ng/mL and clinical stage of organ confined
prostate cancer T1c/T2c (preoperatively normal findings
of pelvic computed tomography and bone scintigraphy)11.
We separated the group of elderly patients according to
the conventional definition, »elderly« has been defined as
a chronological age of 65 years old or older12. Conven-
tionally, »elderly« has been defined as a chronological age
of 65 years or older, while those from 65 to 74 are re-
ferred to as »early elderly« and those over 75 as »late el-
derly«12. We divided early elderly in 2 groups: before and
after 70. Inclusion criteria were fulfiled in 97 patients, 76
patients of them had postoperative pathological stage
(pT2) and 21 had pT3. Clinical and pathomorphological
prognostic parameters that we considered were: age,
PSA value at the time of diagnosis, digitorectal examina-
tion (DRE), Gleason biopsy score, Gleason score in surgi-
cal specimen and positive or negative surgical margins.
Median follow-up time of patients was 44 months (range
7–129 months) and included oncological and urological
control. Clinical and morphological characteristics be-
tween the stages were studied and correlated.
A statistical analysis was performed using Statistica
6.1 software (StatSoft, Inc., Tulsa, OK, USA). Mann-
-Whitney U-test was used to assess the significance of as-
sociation of pT2 and pT3 stage with clinicopathologic
data such as age, PSA, Gleason score of biopsy and
Gleason score of a surgical specimen. The association be-
tween DRE, patients age and surgical margin with pT2
and pT3 stage was evaluated using c2 test. Recurrence-
-free survival analysis was carried out with the Kaplan-
-Meier method. Statistical differences with p value less
than 0.05 were considered significant.
Results
We found no statistical association between age cate-
gories and pT stage (Figure 1).
The evaluation of the number of prostatectomy and
prostate cancer diagnosies in Rijeka University Hospital
Center is showing a rapid increase of the rate of prostate
cancer diagnosies after the year 2001 (Figure 2). The
number of prostate cancer diagnosies was 87 in 2001 and
295 in 2008. Also, the number of prostatectomy in-
creased. The most of them were retropubic. We intro-
duced recently a laparoscopic technique in daily practise.
The pathological stage of patients with prostate can-
cer was compared to clinical parameters such as patients’
age, total serum PSA concentration and DRE (Table 1).
A statistical analysis showed no significant association of
age, PSA concentration and DRE to pT of the disease.
Total serum PSA concentrations between pT groups
demonstrated higher values in patients presented with
pT2 stage (7.5 ng/mL) than in those with pT3 (6.4
ng/mL), but with higher maximal values in these pa-
tients (range 5–37.4). Pathological stage of patients with
prostate cancer was also compared to pathomorpholo-
gical parameters as Gleason score before and after the
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TABLE 1













pos neg pos neg
pT2 69 (66–80) 7.5 (2.8–25) 7 60 6 (2–7) 6 (3–7) 18 58
pT3 68 (66–80) 6.4 (5–37.4) 0 16 6 (4–7) 6 (5–9) 11 10
p value 0.275* 0.641* 0.177** 0.235* 0.003* 0.011**


















Fig. 1. Pathological stage (pT) distribution across age categories
in patients with prostate cancer. White bars represent number of
patients with prostate cancer in pT2, while black bars represent
patients with prostate cancer in pT3. c2 test showed no associa-
tion between pT and patients age (p=0.621).
surgery and to positivity of the surgical margins (Table
1). There was no difference in median values of Gleason
score between biopsy and surgical specimens. Namely,
Gleason score before surgery and that after the surgery
showed a significant correlation (p<0.001, rp=0.475).
Also, Gleason score after the surgery showed a signifi-
cant association to pT (p=0.003), what was not the case
for Gleason score of biopsy specimens. We found higher
frequency of positive surgical margin in tumors with pT3
(90%) than in pT2 (31%) (p=0.011, c2 test). Oncological
and urological control revealed recurrency of the disease
in 8 patients (8.2%). Six of them developed bone meta-
stases, 1 patient had lymph node metastasis and 1 pa-
tient developed local recurrency. Total serum PSA in
thise patients was less than 10 ng/mL. Five of them were
in pT3 group with Gleason score 7. All patients but one
had tumor with positive surgical margins. Recurrence-
-free survival was significantly shorter in patients with
tumors with positive surgical margins (p=0.030 log-rank
test) as well as in patients with pT3 stage (p=0.001,
log-rank test) (Figure 3).
Discussion
Urologists will soon be faced with the reality of a dra-
matic increase of the elderly and by 2030 the population
of men aged 65 years is expected to grow up to >71
milion representing 19.6% of the mankind. Modern med-
icine will prolong life expectancy and according to cur-
rent dana the average survival of a 70-year-old man is 13
years13,14. With the than ageing population, more than
70% of prostate cancer is diagnosed in men aged 65
years with significant life expectancy15. However, there
are still many unanswered questions about the nature
and treatment of prostatic carcinoma in this cohort. We
could not find a relationship between the age and pT
stage as in some previous studies16,17. On the contrary,
the study of Richstone et. al., found that age 70 was as-
sociated with extracapsular extension of the tumor and
upstaging14. PSA testing offers earlier detection of pros-
tatic carcinoma with a lower stage and clinically localized
and potentially curable disease by means of aggressive
therapy such as prostatectomy2,18. This way of treatment
substantially reduces the risk of metastasis and symp-
tomatic local tumor growth19–21. However, a radical pros-
tatectomy can be done in 10–20% of patients because of
late diagnosis of prostatic carcinoma2. In our practise the
frequency of this procedure is within the mentioned per-
centage range (13.7%). Low risk criteria for prostatec-
tomy in our population provide an adequate urological
and oncological control since we have only 7 patients
with progression in metastatic disease and one patient
had local tumor progression. The same conclusion was
made by Rodriguez et al. suggesting that preoperative
PSA values 10 ng/mL significantly predict adequacy of
this way of treatment as a monotherapy22. We did not
find significant differences of PSA values between pT2
and pT3 groups of patients yet the mean of preoperative
PSA was 7.4 in patients with pT2 tumors and 6.4 ng/mL
in a group presenting extraprostatic disease (pT3) with
higher maximal values in these patients (range 5–37.4
ng/mL). Almeida et al. in his study showed that patients
with prostate confined carcinoma presented significantly
lower PSA rates (7.5 ng/mL) in relation to the group of
patients with locally advanced disease (12.5 ng/mL)23.
The same study revealed that patients from group pT2
presented inferior mean values of Gleason when com-
pared to patients in pT3 group as we did in a surgical
specimens analysis. Our findings of Gleason score before
surgery and that after the surgery showed a significant
correlation (p<0.001, rp=0.475). The reason could be a
shift in Gleason scoring by pathologists over the past de-
cade. Some authors presum that pathologists are more
hesitant nowadays to assign low Gleason scores to a diag-
nostic needle biopsy specimen because low scores are fre-
quently upgraded after a review of the surgical spe-
cimen3,24. Results of large studies indicated that the posi-
tive rate of surgical margin after radical prostatectomy is
20%–40%, and contemporary data suggest that the pres-
ence of a positive surgical margin will have an impact on
the patient’s prognosis25. In our study overall positive
surgical margin rate was 29.8 % with higher freequency

























Fig. 2. The number of radical prostatectomy (RP) and prostate
cancer (PC) from 1999–2008.




































Fig. 3. Recurrence free survival in relation to positive surgical
margins status. Kaplan-Meier analysis showed that recurrence-
-free survival was significantly shorter in patients with tumors
with positive surgical margins (p=0.030).
in pT3 tumors up to 90% what is similar to other stu-
dies26–28. Recurrence-free survival time was significantly
shorter in patients with locally advanced tumors and tu-
mors with positive surgical margins. This is in agree-
ment with the results of Bostwick et al. who found that
the impact of a positive margin status on recurrence-free
survival appears to be anatomic and site specific29.
Conclusion
The current data indicated that the presence of posi-
tive surgical margins and pT3 stage are useful in the
prognosis of a recurrence-free survival period in our
group of elderly patients treated with radical prostatec-
tomy.
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PROGNOSTI^KA VRIJEDNOST MORFOLO[KIH I KLINI^KIH PARAMETARA KOD pT2 – pT3
KARCINOMA PROSTATE U LJUDI STARIJE @IVOTNE DOBI
S A @ E T A K
Karcinom prostate je bolest starije `ivotne dobi, ~ija incidencija raste s godinama. Ova studija prikazuje povezanost
izme|u klini~kih i morfolo{kih parametara u lokalno ograni~enom (pT2) i lokalno uznapredovalom (pT3) stadiju karci-
noma prostate. Analizirali smo grupu ljudi starije `ivotne dobi u kojih je u~injena radikalna prostatektomija u razdoblju
izme|u 1999. i 2008. u KBC Rijeka. Nismo na{li statisti~ki zna~ajnu povezanost izme|u pT stadija te starosti bolesnika,
prijeoperacijske vrijednosti prostata specifi~nog antigena, digitorektalnog pregleda i Gleason zbroja dobivenog biop-
sijom. Statisti~ki je prisutna zna~ajna povezanost izme|u ve}eg Gleason zbroja u uzorcima radikalne prostatektomije
kao i ve}a u~estalost pozitivnih kirur{kih rubova u tumora pT3 stadija nego pT2 (p=0.003; p=0.011). Razdoblje bez
znakova povratka bolesti je bio kra}i u bolesnika s pozitivnim kirur{kim rubovima kao i u bolesnika s pT3 stadijem
(p=0.030; p=0.001). Mo`emo zaklju~iti da su tumori vi{eg stadija kao i prisutnost pozitivnih kirur{kih rubova poka-
zatelj lo{ije prognoze u na{ih pacijenata.
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